Focus: CRISPR Therapeutics is a Boston-based biotechnology company focused on CRISPR-Cas9 gene therapy, targeting hematologic malignancies, genetic blood disorders, and autoimmune diseases. The company operates as a mid-cap biotech with a diversified pipeline spanning multiple therapeutic areas.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
2 added, 3 removed. Backfill posture.
Strong platform and lead program catalysts make this a compelling opportunity for gene-therapy specialists willing to tolerate pre-commercial clinical-stage risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CRISPR Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CRISPR Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo